The GLP-1 shortages are over. What happens next?

A federal judge has ruled that compounding pharmacies can’t keep making copies of tirzepatide, the active ingredient in Mounjaro and Zepbound , in a matter of days .

Compounding pharmacies have until March 19 to stop making copies.

A parallel legal battle is playing out over compounded semaglutide, a popular GLP-1 drug, but the court case remains ongoing.

Patients are wondering if compounding purportedly personalized GLP-1 doses might make producing the medication legal beyond the FDA ’s spring deadlines.

The FDA allows these kinds of bespoke doses only when they make a “clinical difference” for the patient.

Many providers are already writing prescriptions for compounded semaglutide with B12 or B6 mixed in.

Expert: Compounding is not intended to be competition for FDA -approved drugs.

“It can be easy to fall for schemes, gimmicks and scams,” says Rickel .

“The weight loss industry, unfortunately, is filled with quick fixes’” Be careful that you don’t commit to buying or subscribing from unreliable sources.

Here, again, your prescriber or doctor can likely help.